Status:
COMPLETED
E07-001: Safety and Efficacy Extension Study of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria Patients
Lead Sponsor:
Alexion Pharmaceuticals, Inc.
Collaborating Sponsors:
CMIC Co, Ltd. Japan
Conditions:
Paroxysmal Nocturnal Hemoglobinuria
Eligibility:
All Genders
12+ years
Phase:
PHASE2
Brief Summary
The objective of this study was to assess the long-term safety and efficacy of eculizumab in hemolytic PNH patients who completed the 4-week screening and 12-week treatment period of the C07-001 study...
Eligibility Criteria
Inclusion
- Patients must have fully completed C07-001 study 12-week treatment period
Exclusion
- Patients who terminated early from the C07-001 study
Key Trial Info
Start Date :
April 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2011
Estimated Enrollment :
27 Patients enrolled
Trial Details
Trial ID
NCT01194804
Start Date
April 1 2008
End Date
March 1 2011
Last Update
September 17 2019
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.